PAN
MCID: PLY017
MIFTS: 58

Polyarteritis Nodosa (PAN)

Categories: Bone diseases, Cardiovascular diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Polyarteritis Nodosa

MalaCards integrated aliases for Polyarteritis Nodosa:

Name: Polyarteritis Nodosa 12 74 52 58 36 54 43 15 17 71 32
Periarteritis 52 71
Polyarteritis 52 71
Pan 52 58
Kussmaul-Maier Disease 58
Periarteritis Nodosa 58

Characteristics:

Orphanet epidemiological data:

58
polyarteritis nodosa
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare circulatory system diseases
Rare renal diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:9810
KEGG 36 H01382
ICD9CM 34 446.0
MeSH 43 D010488
NCIt 49 C26847
SNOMED-CT 67 155441006
ICD10 32 M30.0 M30.1
MESH via Orphanet 44 D010488
ICD10 via Orphanet 33 M30.0
UMLS via Orphanet 72 C0031036
Orphanet 58 ORPHA767
UMLS 71 C0031036 C0264988 C0264992

Summaries for Polyarteritis Nodosa

NIH Rare Diseases : 52 Polyarteritis nodosa (PAN) is a blood vessel disease characterized by inflammation of small and medium-sized arteries (vasculitis ), preventing them from bringing oxygen and food to organs . Most cases occur in the 4th or 5th decade of life, although it can occur at any age. PAN most commonly affects vessels related to the skin, joints, peripheral nerves, gastrointestinal tract, heart, eyes, and kidneys. Symptoms are caused by damage to affected organs and may include fever, fatigue, weakness, loss of appetite, weight loss, muscle and joint aches, rashes, numbness, and abdominal pain. The underlying cause of PAN is unknown. Treatment involves medicines to suppress inflammation and the immune system , including steroids .

MalaCards based summary : Polyarteritis Nodosa, also known as periarteritis, is related to cutaneous polyarteritis nodosa and churg-strauss syndrome. An important gene associated with Polyarteritis Nodosa is ADA2 (Adenosine Deaminase 2), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Methotrexate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include kidney, skin and neutrophil, and related phenotypes are fever and weight loss

Disease Ontology : 12 A vasculitis that is characterized by necrotizing inflammation of medium or small arteries.

KEGG : 36 Polyarteritis nodosa is a systemic necrotizing vasculitis that affects medium and small muscular arteries. The ensuing tissue ischemia can affect any organ, including the skin, musculoskeletal system, kidneys, gastrointestinal tract, and the cardiovascular and nervous systems. In most cases, onset of the disease occurred during childhood. Polyarteritis nodosa is most often primary. Recessive mutations in the adenosine deaminase 2 (ADA2)-encoding gene CECR1 have been found from patients of this disease.

Wikipedia : 74 Polyarteritis nodosa (PAN), is a systemic necrotizing inflammation of blood vessels (vasculitis)... more...

Related Diseases for Polyarteritis Nodosa

Diseases in the Polyarteritis Nodosa family:

Systemic Polyarteritis Nodosa Secondary Polyarteritis Nodosa
Primary Polyarteritis Nodosa

Diseases related to Polyarteritis Nodosa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 794)
# Related Disease Score Top Affiliating Genes
1 cutaneous polyarteritis nodosa 35.3 SMAD3 IFNA2
2 churg-strauss syndrome 32.1 PRTN3 MPO HLA-DRB1
3 kawasaki disease 31.8 SELL SELE IL6 GPT CRP
4 microscopic polyangiitis 31.8 MPO HLA-DRB1
5 familial mediterranean fever 31.6 MEFV IL6 CRP
6 purpura 31.5 MEFV IL6 CRP APOH
7 mononeuritis multiplex 31.4 PRTN3 MPO CRP
8 orchitis 31.4 IL6 IFNA2 CRP
9 intestinal perforation 31.3 IL6 GPT CRP
10 glomerulonephritis 31.2 VCAM1 PRTN3 MPO ICAM1
11 granulomatous angiitis 31.1 PRTN3 CRP
12 peripheral nervous system disease 31.1 PRTN3 IL6 GPT FGF2 CRP
13 pyelonephritis 31.0 IL6 GPT CRP
14 mononeuropathy 31.0 PRTN3 MPO CRP
15 thrombocytosis 30.9 SELP IL6 CRP
16 anca-associated vasculitis 30.9 PRTN3 MPO
17 scleritis 30.9 SELE PRTN3 CRP
18 livedoid vasculitis 30.9 APOH ADA2
19 pericarditis 30.9 MEFV IL6 CRP
20 hepatic infarction 30.9 GPT APOH
21 thrombophlebitis 30.8 SELP CRP APOH
22 cryoglobulinemia 30.8 IL6 IFNA2 HLA-DRB1 GPT APOH
23 retinal artery occlusion 30.8 IL6 ICAM1 CRP APOH
24 antiphospholipid syndrome 30.8 VCAM1 SELP SELE CRP APOH
25 disseminated intravascular coagulation 30.8 SELE IL6 GPT CRP
26 brucellosis 30.8 SELL MPO MEFV IL6 CRP
27 colitis 30.8 SMAD3 MPO IL6 HLA-DRB1
28 rapidly progressive glomerulonephritis 30.8 PRTN3 MPO ICAM1 CRP
29 rheumatic fever 30.8 IL6 ICAM1 HLA-DRB1
30 exanthem 30.8 PRTN3 MPO MEFV IL6 GPT CRP
31 systemic scleroderma 30.8 SELP SELE IL6 CRP
32 amyloidosis aa 30.7 MEFV CRP
33 connective tissue disease 30.7 SMAD3 IL6 HLA-DRB1 CRP APOH
34 intestinal obstruction 30.7 IL6 GPT CRP
35 adult-onset still's disease 30.7 MEFV IL6 HLA-DRB1 CRP
36 appendicitis 30.7 MPO IL6 CRP
37 herpes zoster 30.7 IFNA2 HLA-DRB1 CRP
38 sudden sensorineural hearing loss 30.7 IL6 APOH
39 psoriatic arthritis 30.7 SELE IL6 HLA-DRB1 CRP
40 granulomatosis with polyangiitis 30.7 SELE PRTN3 MPO CRP
41 vasculitis 30.6 VCAM1 SELP SELL SELE PRTN3 MPO
42 allergic hypersensitivity disease 30.6 VCAM1 SELL SELE ICAM1
43 autoimmune disease 30.6 VCAM1 PRTN3 IL6 HLA-DRB1 CRP APOH
44 tolosa-hunt syndrome 30.6 PRTN3 CRP
45 erysipelas 30.6 MEFV IL6 CRP
46 fabry disease 30.6 IL6 ICAM1 CRP
47 tenosynovitis 30.6 PRTN3 IL6 CRP
48 sarcoidosis 1 30.6 SELP ICAM1 HLA-DRB1 CRP
49 mixed connective tissue disease 30.6 IL6 HLA-DRB1 APOH
50 rheumatic heart disease 30.6 VCAM1 IL6 HLA-DRB1

Graphical network of the top 20 diseases related to Polyarteritis Nodosa:



Diseases related to Polyarteritis Nodosa

Symptoms & Phenotypes for Polyarteritis Nodosa

Human phenotypes related to Polyarteritis Nodosa:

58 31 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
2 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
3 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
4 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
5 abnormality of the kidney 58 31 frequent (33%) Frequent (79-30%) HP:0000077
6 elevated c-reactive protein level 58 31 frequent (33%) Frequent (79-30%) HP:0011227
7 polyneuritis 58 31 frequent (33%) Frequent (79-30%) HP:0031003
8 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
9 erythema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010783
10 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
11 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
12 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
13 hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0000822
14 abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0011024
15 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
16 raynaud phenomenon 58 31 occasional (7.5%) Occasional (29-5%) HP:0030880
17 sensory axonal neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003390
18 morphological central nervous system abnormality 31 occasional (7.5%) HP:0002011
19 abnormality of the eye 58 31 very rare (1%) Very rare (<4-1%) HP:0000478
20 cardiomyopathy 58 31 very rare (1%) Very rare (<4-1%) HP:0001638
21 pleuritis 58 31 very rare (1%) Very rare (<4-1%) HP:0002102
22 peripheral neuropathy 58 Frequent (79-30%)
23 abnormal lung morphology 58 Occasional (29-5%)
24 abnormality of the nervous system 58 Occasional (29-5%)
25 abnormality of cardiovascular system morphology 58 Occasional (29-5%)
26 morphological abnormality of the central nervous system 58 Occasional (29-5%)
27 abnormality of skin morphology 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability ratio GR00368-A 9.28 APOH HLA-DRB1 IFNA2 MEFV MPO MSN

MGI Mouse Phenotypes related to Polyarteritis Nodosa:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 CRP FGF2 ICAM1 IL6 MPO PECAM1
2 cellular MP:0005384 10.03 FGF2 ICAM1 IL6 MEFV MSN PECAM1
3 hematopoietic system MP:0005397 10 FGF2 ICAM1 ICAM2 IL6 MEFV MPO
4 homeostasis/metabolism MP:0005376 9.8 APOH CRP FGF2 ICAM1 IL6 MEFV
5 immune system MP:0005387 9.47 CRP ICAM1 ICAM2 IL6 MEFV MPO

Drugs & Therapeutics for Polyarteritis Nodosa

Drugs for Polyarteritis Nodosa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
4
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
5
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
6 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
10 Dermatologic Agents Phase 4
11 Gastrointestinal Agents Phase 4
12 Hormones Phase 4
13 Methylprednisolone Acetate Phase 4
14 Antineoplastic Agents, Hormonal Phase 4
15 Antiemetics Phase 4
16 Hormone Antagonists Phase 4
17 glucocorticoids Phase 4
18 Neuroprotective Agents Phase 4
19 Protective Agents Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Antitubercular Agents Phase 4
22 Antibiotics, Antitubercular Phase 4
23
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
24
Azathioprine Approved Phase 2 446-86-6 2265
25
leucovorin Approved Phase 2 58-05-9 6006 143
26
Colchicine Approved Phase 2 64-86-8 2833 6167
27
Dapsone Approved, Investigational Phase 2 80-08-0 2955
28
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
29
Ethanol Approved Phase 2 64-17-5 702
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31 Anti-HIV Agents Phase 2
32 Reverse Transcriptase Inhibitors Phase 2
33 Antiviral Agents Phase 2
34 Anti-Retroviral Agents Phase 2
35 Antimetabolites Phase 2
36 Folic Acid Antagonists Phase 2
37 Vitamin B Complex Phase 2
38 Folate Phase 2
39 Vitamin B9 Phase 2
40 Anti-Infective Agents Phase 2
41 Anti-Bacterial Agents Phase 2
42 Tubulin Modulators Phase 2
43 Antiprotozoal Agents Phase 2
44 Antiparasitic Agents Phase 2
45 Antimalarials Phase 2
46 Antimitotic Agents Phase 2
47 Narcotics Phase 2
48 Narcotic Antagonists Phase 2
49
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
50
Mesna Approved, Investigational Phase 1 3375-50-6 598

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 Patients Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
4 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial. Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
5 Lamivudine for Chronic Hepatitis B Completed NCT00001457 Phase 2 Lamivudine
6 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
7 A Randomized Multicenter Study for Isolated Skin Vasculitis Recruiting NCT02939573 Phase 2 Colchicine;Dapsone;Azathioprine
8 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
9 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
10 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
11 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
12 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Unknown status NCT02006134
13 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
14 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
15 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
16 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
17 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
18 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
19 A Staged Therapeutic Approach Using Cyclophosphamide and Methotrexate in the Treatment of Wegener's Granulomatosis and Related Vasculitides Completed NCT00001473
20 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
21 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
22 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
23 Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis Recruiting NCT02257866
24 Longitudinal Protocol of Polyarteritis Nodosa Active, not recruiting NCT00315406
25 VCRC Genetic Repository One-Time DNA Protocol Active, not recruiting NCT01241305
26 Arthritis in Assiut University Children Hospital Not yet recruiting NCT04326582

Search NIH Clinical Center for Polyarteritis Nodosa

Cochrane evidence based reviews: polyarteritis nodosa

Genetic Tests for Polyarteritis Nodosa

Anatomical Context for Polyarteritis Nodosa

MalaCards organs/tissues related to Polyarteritis Nodosa:

40
Kidney, Skin, Neutrophil, Lung, Liver, Eye, Heart

Publications for Polyarteritis Nodosa

Articles related to Polyarteritis Nodosa:

(show top 50) (show all 3439)
# Title Authors PMID Year
1
Mutations/polymorphisms in a monogenetic autoinflammatory disease may be susceptibility markers for certain rheumatic diseases: lessons from the bedside for the benchside. 61 54
19796529 2009
2
Prevalence of the MEFV gene mutations in childhood polyarteritis nodosa. 61 54
18035151 2007
3
Cytomegalovirus infection in systemic necrotizing vasculitis: causative agent or opportunistic infection? 54 61
11149660 2000
4
Clinical, laboratory and molecular characteristics of children with Familial Mediterranean Fever-associated vasculitis. 54 61
10709887 2000
5
[A reversible posterior leukoencephalopathy syndrome in a patient with classical polyarteritis nodosa]. 54 61
9146079 1997
6
Anti-neutrophil cytoplasmic antibody for proteinase 3 in a child with polyarteritis nodosa. 54 61
7754755 1995
7
[Autoantibodies associated with vasculitis]. 61 54
7933581 1994
8
Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. 61 54
7912504 1994
9
Elevations of neutrophil proteinase 3 in serum of patients with Wegener's granulomatosis and polyarteritis nodosa. 61 54
7907475 1994
10
Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. 61 54
1466365 1992
11
[Antineutrophil cytoplasmic antibodies--ANCA]. 61 54
1464072 1992
12
Polyarteritis nodosa with genital necrosis. 61
32518757 2020
13
The ratio of CD163-positive macrophages to Iba1-positive macrophages is low in the intima in the early stage of cutaneous arteritis. 61
32578130 2020
14
Polyarteritis nodosa isolated to muscles-A case series with a review of the literature. 61
31959304 2020
15
Successful treatment of tumor necrosis factor inhibitor-resistant cutaneous polyarteritis nodosa with tocilizumab. 61
32515121 2020
16
Comorbidities in familial Mediterranean fever: analysis of 2000 genetically confirmed patients. 61
31598713 2020
17
Periodic fever syndromes: a patient diagnosed with recurrent Kawasaki disease. 61
32524933 2020
18
Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. 61
32276138 2020
19
Two cases of ADA2 deficiency presenting as childhood polyarteritis nodosa: novel ADA2 variant, atypical CNS manifestations, and literature review. 61
32535845 2020
20
Bilateral interstitial keratitis, erythema nodosum and atrial fibrillation as presenting signs of polyarteritis nodosa. 61
32140612 2020
21
Evaluating FMX-101 as a promising therapeutic for the treatment of acne. 61
32037906 2020
22
Clusters in Pediatric Rheumatic Diseases. 61
32436006 2020
23
[Cutaneous vasculitis and vasculopathy : Differential diagnosis in biopsies of the lower extremities]. 61
32377833 2020
24
Survey of Japanese dermatological vasculitis specialists on cases of cutaneous arteritis (cutaneous polyarteritis nodosa). 61
32096266 2020
25
Reuma.pt/vasculitis - the Portuguese vasculitis registry. 61
32370776 2020
26
Severe and Refractory Polyarteritis Nodosa Associated With CECR1 Mutation and Dramatic Response to Infliximab in Adulthood. 61
29916967 2020
27
Endovascular Treatment of Distal Lenticulostriate Artery Aneurysm by Selective Catheterization of Artery with Balloon-Blocking Technique: 2-Dimensional Video Illustration. 61
31954888 2020
28
Cutaneous arteriolitis: A novel cutaneous small vessel vasculitis disorder clinicopathologically different from cutaneous polyarteritis nodosa and cutaneous venulitis. 61
32338386 2020
29
Choroidal vascularity index as a biomarker of systemic inflammation in childhood Polyarteritis Nodosa and adenosine deaminase-2 deficiency. 61
32245490 2020
30
Alpha-1 Antitrypsin Deficiency in an Infant With Polyarteritis Nodosa. 61
32251054 2020
31
Systemic Lupus Erythematosus Associated With Polyarteritis Nodosa-Like Muscular Vasculitis. 61
32345843 2020
32
Concurrence of polyarteritis nodosa and multiple sclerosis. 61
31769115 2020
33
Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. 61
32345372 2020
34
Tocilizumab treatment for polyarteritis nodosa. 61
32182367 2020
35
The "Nodes" in Polyarteritis Nodosa-Coronary Artery Aneurysms. 61
32073524 2020
36
Mastitis in Autoimmune Diseases: Review of the Literature, Diagnostic Pathway, and Pathophysiological Key Players. 61
32235676 2020
37
Inpatient burden and association with comorbidities of polyarteritis nodosa: National Inpatient Sample 2014. 61
31362895 2020
38
Provisional seven-item criteria for the diagnosis of polyarteritis nodosa. 61
32107599 2020
39
A 9.5-year-old boy with recurrent neurological manifestations and severe hypertension, treated initially for polyarteritis nodosa, was subsequently diagnosed with adenosine deaminase type 2 deficiency (DADA2) which responded to anti-TNF-α. 61
30642227 2020
40
Lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosa: Clinicopathologic comparison with blinded histologic assessment. 61
32044177 2020
41
Autoimmune conditions and primary central nervous system lymphoma risk among older adults. 61
31625136 2020
42
A Non-smoking Woman with Anti-phospholipid Antibodies Proved to Have Thromboangiitis Obliterans. 61
31588083 2020
43
Is macular lymphocytic arteritis limited to the skin? Long-term follow-up of seven patients. 61
31889596 2020
44
Hypertensive Crisis: The Other Side of Polyarteritis Nodosa. 61
32015938 2020
45
Successful treatment of painful chronic wounds with amniotic and umbilical cord tissue: A case series. 61
32477550 2020
46
A Monogenic Disease with a Variety of Phenotypes: Deficiency of Adenosine Deaminase 2. 61
31043544 2020
47
Measuring Vasculitis with Numbers: Outcome Scores. 61
31804163 2020
48
An Atypical Case of Vasculitis: When 'Occult' 18FDG-PET Scan Findings Create a Classification Dilemma. 61
32015964 2020
49
Recognition and Management of Cutaneous Polyarteritis Nodosum Versus Livedoid Vasculitis: A Case Report. 61
32140348 2020
50
Polyarteritis Nodosa: an unusual case of paraneoplastic process in renal cell carcinoma. 61
32128064 2020

Variations for Polyarteritis Nodosa

Expression for Polyarteritis Nodosa

Search GEO for disease gene expression data for Polyarteritis Nodosa.

Pathways for Polyarteritis Nodosa

Pathways related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 VCAM1 SELL PRTN3 PECAM1 MPO MEFV
2
Show member pathways
13.27 VCAM1 PRTN3 IL6 IFNA2 ICAM1 HLA-DRB1
3
Show member pathways
13.2 SELP SELL SELE PRTN3 PECAM1 IFNA2
4
Show member pathways
12.72 MSN IL6 IFNA2 ICAM1 HLA-DRB1
5
Show member pathways
12.64 VCAM1 PECAM1 ICAM2 ICAM1 FGF2
6 12.24 SMAD3 IL6 ICAM1 HLA-DRB1
7
Show member pathways
12.22 MPO IL6 ICAM1 CRP
8
Show member pathways
12.12 SELP SELL SELE PECAM1
9
Show member pathways
12.04 VCAM1 PECAM1 ICAM2 ICAM1
10 11.97 VCAM1 SELE PECAM1 ICAM1
11 11.94 VCAM1 SELL ICAM2 ICAM1
12 11.86 SELL MPO IL6 IFNA2
13 11.84 VCAM1 IL6 ICAM1 FGF2
14 11.81 VCAM1 SELE IL6 ICAM1
15 11.71 SELE IL6 ICAM1
16 11.65 SELL IL6 IFNA2
17 11.65 VCAM1 SMAD3 SELE IL6 ICAM1
18
Show member pathways
11.5 VCAM1 SELE IL6 ICAM1
19 11.4 VCAM1 SELP SELL SELE PECAM1 ICAM2
20 11.39 VCAM1 SELE ICAM1
21 11.36 VCAM1 ICAM2 ICAM1
22 11.23 SELP MPO IL6 ICAM2 ICAM1
23 11.19 VCAM1 SELE IL6 ICAM1
24 11.13 VCAM1 SELP SELE PECAM1 IL6 ICAM1
25 10.81 VCAM1 MPO ICAM1

GO Terms for Polyarteritis Nodosa

Cellular components related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.97 VCAM1 PRTN3 PECAM1 MSN MPO ICAM1
2 integral component of plasma membrane GO:0005887 9.76 VCAM1 SELP SELL SELE PECAM1 ICAM2
3 membrane raft GO:0045121 9.73 SELE PRTN3 PECAM1 ICAM1
4 cell surface GO:0009986 9.73 VCAM1 SELL MSN ICAM1 HLA-DRB1 APOH
5 azurophil granule lumen GO:0035578 9.65 PRTN3 MPO ADA2
6 cell periphery GO:0071944 9.58 PECAM1 MSN ICAM2
7 microvillus GO:0005902 9.54 VCAM1 MSN ICAM2
8 extracellular space GO:0005615 9.53 VCAM1 SELP SELE PRTN3 PECAM1 MSN
9 uropod GO:0001931 9.46 MSN ICAM2
10 external side of plasma membrane GO:0009897 9.43 VCAM1 SELP SELL PECAM1 ICAM1 HLA-DRB1

Biological processes related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.97 SELL PRTN3 PECAM1 MPO ADA2
2 cell adhesion GO:0007155 9.95 VCAM1 SELP SELL SELE PECAM1 ICAM2
3 inflammatory response GO:0006954 9.93 SELP SELE MEFV IL6 IFNA2 CRP
4 extracellular matrix organization GO:0030198 9.89 VCAM1 PECAM1 ICAM2 ICAM1 FGF2
5 regulation of immune response GO:0050776 9.88 VCAM1 SMAD3 SELL ICAM2 ICAM1
6 cytokine-mediated signaling pathway GO:0019221 9.85 VCAM1 PRTN3 IL6 IFNA2 ICAM1 FGF2
7 response to lipopolysaccharide GO:0032496 9.83 SELP SELE MPO ICAM1
8 cell-cell adhesion GO:0098609 9.81 VCAM1 PECAM1 ICAM2 ICAM1
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 PECAM1 IL6 IFNA2
10 interferon-gamma-mediated signaling pathway GO:0060333 9.73 VCAM1 ICAM1 HLA-DRB1
11 leukocyte migration GO:0050900 9.63 SELP SELL SELE PECAM1 MSN ICAM1
12 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.62 VCAM1 SELP SELE ICAM1
13 establishment of endothelial barrier GO:0061028 9.61 PECAM1 MSN ICAM1
14 negative regulation of lipid storage GO:0010888 9.58 IL6 CRP
15 positive regulation of leukocyte tethering or rolling GO:1903238 9.55 SELP SELE
16 neutrophil extravasation GO:0072672 9.54 PRTN3 PECAM1
17 membrane to membrane docking GO:0022614 9.43 VCAM1 MSN ICAM1
18 leukocyte tethering or rolling GO:0050901 9.26 VCAM1 SELP SELL SELE
19 leukocyte cell-cell adhesion GO:0007159 9.1 VCAM1 SELP SELE PECAM1 MSN ICAM1

Molecular functions related to Polyarteritis Nodosa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion molecule binding GO:0050839 9.5 VCAM1 SELL MSN
2 integrin binding GO:0005178 9.46 VCAM1 ICAM2 ICAM1 FGF2
3 glycosphingolipid binding GO:0043208 9.26 SELP SELL
4 oligosaccharide binding GO:0070492 9.13 SELP SELL SELE
5 heparin binding GO:0008201 9.1 SELP SELL MPO FGF2 APOH ADA2

Sources for Polyarteritis Nodosa

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....